The Nuclear Company Hires Former Tesla Security Lead Mike Marty as VP of Security.

Oracle announces two executives, Clay Magouyrk and Mike Sicilia, as co-CEOs to replace outgoing CEO Safra Catz. Pfizer agrees to buy obesity startup Metsara for $4.9 billion, while Kenvue shares slump on reports of a potential link between Tylenol and autism.

Oracle Corporation (NYSE:ORCL) has announced significant leadership changes, with Clay Magouyrk and Mike Sicilia being appointed as co-CEOs, replacing outgoing CEO Safra Catz. Catz will transition to the role of Executive Vice Chair of the Board of Directors Oracle Corporation Announces Promotion of Clay Magouyrk and Mike Sicilia to CEOs; Safra Catz Appointed Executive Vice Chair of the Board of Directors^[1]. This move comes as Oracle strengthens its position in artificial intelligence (AI) and cloud infrastructure.

Magouyrk, previously President of Oracle Cloud Infrastructure (OCI), and Sicilia, former President of Oracle Industries, will jointly lead Oracle's AI-focused future. The dual-CEO structure combines Magouyrk's infrastructure expertise with Sicilia's applications knowledge, aligning with Oracle's strategic focus on AI Oracle Corporation Announces Promotion of Clay Magouyrk and Mike Sicilia to CEOs; Safra Catz Appointed Executive Vice Chair of the Board of Directors^[1].

Additionally, Oracle has promoted Mark Hura to President of Global Field Operations and Doug Kehring to Principal Financial Officer. The company reaffirmed its financial guidance from September 9, 2025. The retention of Safra Catz as Executive Vice Chair and Larry Ellison as CTO maintains significant leadership continuity, creating a leadership triumvirate Oracle Corporation Announces Promotion of Clay Magouyrk and Mike Sicilia to CEOs; Safra Catz Appointed Executive Vice Chair of the Board of Directors^[1].

Separately, Pfizer Inc. (PFE) agreed to acquire obesity drug developer Metsera Inc. (MTSR) for approximately $4.9 billion. The deal includes an enterprise value of $4.9 billion, with Pfizer purchasing all shares of Metsera for $47.50 per share in cash. The acquisition will give Pfizer access to Metsera's portfolio of oral and injectable incretin, non-incretin, and combination therapeutic candidates Pfizer Strikes $4.9 Billion Deal to Buy Obesity Drug Developer Metsera^[2].

Pfizer's Chief Executive Albert Bourla stated, "We are excited to apply our deep cardiometabolic experience and manufacturing and commercial infrastructure to accelerate a portfolio that includes potential best-in-class injectables." The deal requires approval by regulators and clearance from Metsera's shareholders and is expected to complete in the fourth quarter. Pfizer will provide updates to its financial outlook during its upcoming quarterly results Pfizer Strikes $4.9 Billion Deal to Buy Obesity Drug Developer Metsera^[2].

Meanwhile, Kenvue shares have slumped on reports of a potential link between Tylenol and autism. The company has not yet commented on the allegations .